Indivior Plc (INDV.L), a specialty pharma company, Thursday reported a pre-tax loss for the third-quarter, amidst exceptional costs and other adjustments. However, the company recorded a rise in net revenue.
In addition, the drug maker reaffirmed its annual guidance. For the three-month period to September 30, the company posted a pre-tax loss of $181 million, compared with a profit of $54 million, recorded for the same period previous year.
After tax, loss stood at $135 million or $0.98 per share as against last year's profit of $41 million or $0.28 per share.
Excluding items, profit improved to $49 million or $0.34 per share from $43 million or $0.29 per share in 2022.
Operating loss was at $183 million, compared with profit of $56 million a year ago. This is mainly due to exceptional costs and other adjustments of $243 million related to the increase in provisions linked to the Antitrust MDL and an intellectual property-related matter.
Excluding items, operating profit stood at $60 million as against previous year's $58 million.
Selling, general, and administrative expenses surged to $390 million from last year's $115 million.
Net revenue was $271 million, up from last year's $232 million.
Looking ahead, for the full year, Indivior still expects to post net revenue of $1.030 billion to $1.090 billion, reflecting a growth of 18 percent at the mid-point of the last year's revenue.
Indivior continues to project its adjusted operating income to move up from last year's $212 million.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.